LIBERDI LTD

Their core work

LIBERDI LTD is an Israeli medical device company developing portable peritoneal dialysis (PD) systems designed for home use. Their core product — the Warrick X1 — combines a simplified dialysis workflow with an integrated infection detection system and IoT-based remote monitoring, addressing the two main barriers to home PD adoption: complexity and the risk of peritonitis going undetected. They target the large and underserved population of chronic kidney disease patients who are currently hospital-dependent for dialysis. Their work spans hardware design, embedded software, and connected health infrastructure.

What they specialise in

How they've shifted over time

LIBERDI's H2020 trajectory follows a tight, deliberate arc rather than a pivot: in 2018 they ran a short Phase 1 feasibility study (LPPDS) to validate the concept of a portable peritoneal dialysis device, with no tagged technology keywords. By 2019 they had moved directly into Phase 2 full product development under Warrick X1, where the keyword set reveals a much richer technical stack — infection detection, IoT connectivity, and remote monitoring layered on top of the core dialysis engineering. There is no domain shift; instead, the evolution shows the expected deepening from proof-of-concept to integrated product, with digital health capabilities added as the device matured.

LIBERDI is on a commercialisation trajectory — having completed Phase 2 EU funding by 2022, they are likely in clinical validation or early market entry for the Warrick X1, making them a potential partner for distribution, clinical trial networks, or kidney care service providers rather than for further R&D.

How they like to work

LIBERDI has operated as a solo SME in both EU projects, using the SME Instrument — a funding scheme that does not require a consortium and is designed for single companies with a clear commercial product vision. They led both projects as coordinator with no recorded consortium partners, which is consistent with a product-driven startup protecting IP and maintaining full control of development. Working with them means engaging directly with the company rather than through a research network.

LIBERDI has no recorded EU consortium partners across either project, which reflects the solo-beneficiary model of the SME Instrument rather than an isolated research culture. Their collaboration footprint within H2020 is essentially a direct company-to-EU-Commission relationship.

What sets them apart

LIBERDI occupies a specific niche at the intersection of nephrology and connected health: they are building a home dialysis device that is both simpler to operate and actively monitors for the infection complication (peritonitis) that most often drives patients back to hospital. Few SMEs combine dialysis hardware, infection biosensing, and IoT telemetry in a single product. As an Israeli company successfully funded under H2020, they also bridge EU and Israeli health-tech ecosystems, which can be an asset for consortia that need that geographic link.

Highlights from their portfolio

• Warrick X1
  The flagship project — €2.16M Phase 2 SME Instrument award for a full home dialysis system with integrated infection detection and IoT monitoring, representing one of the larger single-company medtech grants in the SME scheme.
• LPPDS
  The Phase 1 feasibility study that de-risked the concept and secured the pathway to the much larger Warrick X1 investment, demonstrating a disciplined SME Instrument strategy.